CDKN1A and colorectal cancer: Expression of CDKN1A, which was previously shown to increase with 5-AzaC treatment [30] and of CDKN2A, a gene known to be frequently methylated in colorectal cancers [31], were used as positive controls and showed increased transcription in most cell lines.